Wedbush Initiates “Outperform” Rating for Magenta Therapeutics (MGTA) With a $22.0 Price Target

July 16, 2018 - By Billy Entrekin

Why Has Wedbush Given Magenta Therapeutics (MGTA) a $22.0 Price Target

Analysts at Wedbush has begun coverage on shares of Magenta Therapeutics (MGTA) in an analyst note sent to clients and investors on Monday, 16 July. The financial firm set “Outperform” rating on the $417.52 million market cap company.

The stock decreased 3.97% or $0.53 during the last trading session, reaching $12.83. About 125,530 shares traded. Magenta Therapeutics, Inc. (MGTA) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. The company has market cap of $417.52 million. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. It currently has negative earnings. The firm was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016.

More notable recent Magenta Therapeutics, Inc. (NASDAQ:MGTA) news were published by: Nasdaq.com which released: “Retailers, Markets React To Supreme Court Ruling On Online Sales Taxes” on June 21, 2018, also 247Wallst.com with their article: “IPO News This Week: A Record 12 IPOs Coming to Market” published on June 24, 2018, Nasdaq.com published: “Nasdaq’s Hot First Day of Summer – Six IPOs Join our Market” on June 22, 2018. More interesting news about Magenta Therapeutics, Inc. (NASDAQ:MGTA) were released by: Benzinga.com and their article: “Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful” published on July 16, 2018 as well as Benzinga.com‘s news article titled: “38 Biggest Movers From Friday” with publication date: July 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.